Mauro C.
- Country
- Italy
- Department
- UOC Oncologia Medica Universitaria
Research Overview
- Phase III Trial of BI 764532 Plus Carboplatin and Etoposide Versus Carboplatin and Etoposide in Previously Untreated DLL3-Positive Advanced Extrapulmonary Neuroendocrine Carcinoma
- Phase 3 Trial of Octreotide Subcutaneous Depot vs. Octreotide LAR or Lanreotide ATG in Unresectable/Metastatic GEP-NET Patients
- Evaluation of Cabozantinib and Lanreotide Combination in Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: A Phase II Clinical Trial
Data & Insights
Has run more than one trial at 65 of 154 partner sites.
Specializations
Neuroendocrine Cancer Treatment
This investigator specializes in treating various forms of neuroendocrine tumors, with particular emphasis on pulmonary large-cell neuroendocrine carcinoma (LCNEC) and gastroenteropancreatic neuroendocrine tumors (GEP-NET).
- Metastatic LCNEC Management
- GEP-NET Treatment Strategies
- Thoracic NET Therapeutics
The investigator focuses on advanced treatment approaches for unresectable and metastatic cases.
Innovative Therapeutic Combinations
The investigator explores novel therapeutic combinations including immunotherapy agents and targeted therapies for neuroendocrine cancers.
- Immunotherapy Integration
- Combined Modality Treatment
- Maintenance Therapy Approaches
Their work encompasses both conventional chemotherapy and newer biological treatments.
Biomarker Research
The investigator studies molecular targets and tissue biomarkers in neuroendocrine tumors to enhance treatment efficacy.
- Predictive Biomarker Identification
- Treatment Response Markers
- Molecular Target Analysis
Their research includes evaluation of specific markers like MET, AXL, and VEGFR2.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.